Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

NCT00791479 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of the medication LY2189265 on blood sugar control in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 167 people

Who can join Ages 18–75 · all sexes

Timeline Started 2008-12 · est. completion 2010-01

Where 46 sites · Croatia, Denmark, India, Mexico, Poland, Puerto Rico, Russia, Spain, United States

What this study is testing ClinicalTrials.gov NCT00791479 ↗

Description as written by the study sponsor.

This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.

Treatments tested

LY2189265 and Lifestyle Measures also known as Dulaglutide Drug

Subcutaneous injection once-weekly for up to 12 weeks
Placebo solution and Lifestyle Measures Drug

Subcutaneous injection once-weekly for up to 12 weeks

Main thing measured	Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00791479 ↗